Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
TYK Medicines Wins China Approval for Asandeutertinib in EGFR-Mutant NSCLC With Brain Metastases
China’s NMPA has granted conditional approval to asandeutertinib (TY-9591), TYK Medicines’ brain-penetrant, deuterated EGFR inhibitor, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer with central nervous…
Biokin’s Iza-bren hits Phase 3 PFS endpoint in EGFR-Mutant NSCLC, marking 4th positive Phase 3 trial
Sichuan Biokin Pharmaceutical’s izalontamab brengitecan (iza-bren, BL-B01D1) has achieved another major clinical milestone, with the company reporting that its Phase 3 BL-B01D1-301 study in previously treated EGFR-mutant non-small cell lung cancer…